Kura Oncology to Report Third Quarter 2025 Financial Results

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and provide a corporate update.

The live webcast and archived replay will be available on the company’s investor relations website at www.kuraoncology.com.

News Market Reaction – KURA

-2.38%

-2.38% Session close to close

In the Oct 29 session, KURA declined 2.38%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2025 financial results on Tuesday, November 4, 2025, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update.

The live webcast and archived replay of the event may be accessed on the investor relations section of the Company’s website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

When will KURA report third quarter 2025 financial results?

KURA will report results on Tuesday, November 4, 2025 before U.S. markets open.

What time is the KURA Q3 2025 conference call and webcast?

The call and webcast are scheduled for 8:00 a.m. ET / 5:00 a.m. PT on November 4, 2025.

Where can I access the KURA live webcast and replay for Q3 2025?

The live webcast and archived replay will be available on KURA’s investor relations website at www.kuraoncology.com.

Will KURA management provide a corporate update during the Q3 2025 call?

Yes, management will discuss the financial results and provide a corporate update during the conference call.

Is the KURA Q3 2025 report timed before U.S. market open?

Yes, the company will release its third quarter 2025 financial results before U.S. financial markets open on November 4, 2025.